Boston Scientific, Guidant Close The Deal Following FTC Approval
This article was originally published in The Gray Sheet
Boston Scientific closed its $28 bil. acquisition of Guidant on April 21, one day after the Federal Trade Commission approved the deal - the largest medical device acquisition in history
You may also be interested in...
The previously rumored acquisition was announced on April 28, with the firms touting their extensive synergies in the cardiovascular space.
Boston Scientific will pay Johnson & Johnson $600 million to settle allegations that cardiovascular device firm Guidant breached a merger agreement with J&J in 2006, a far cry from the $7 billion sought by J&J
Abbott's SPIRIT III trial for its Xience V everolimus-eluting stent bodes well for the device's market potential and points to a new direction for stent manufacturers' premarket relationship with FDA